Cellectis (NASDAQ:CLLS) Stock, Quote.Headers.trade-ideas

Cellectis

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Earnings

News

Penny Stocks

Upgrades

Markets

Analyst Ratings

CLLS

Cellectis S.A. (NASDAQ: CLLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

Cellectis Upgraded to Buy: Here&#39;s Why

Small Cap

Intraday Update

Movers

Trading Ideas

ACLX

ACXP

AIRE

ALPN

AUDC

AVNW

AWRE

BHIL

CARS

CFLT

CNTB

CRAI

CROX

DASH

DRIO

EGHT

ERII

FROG

FSLY

HOWL

HYZN

INFA

JAKK

JOBY

LMDX

LMND

LOCL

LSPD

LYFT

MCRB

NARI

NVST

OLIT

OMCL

OMGA

OPEN

OTLK

PBLA

PCOR

PKOH

PLPC

PLTR

POET

PTVE

PYPL

QCOM

QNST

RCKY

RELY

ROKU

RVLV

SABR

SBGI

SEDG

SGMO

SHOP

STAA

TENB

THTX

VIRI

XRAY

Gainers


	OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.


Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

ALBT

SIEN

Gainers

LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting determination.

Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Cellectis S.A. - American Depositary Shares

Cellectis SA

CEVA

CEVA Says It Inked Pact With Edge Impulse To Enable Faster, Easier Development Of Edge AI Applications

Italian automaker Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) is reportedly looking for a new CEO to replace Carlos Tavares.
What Happened: Tavares took the helm of the company in 2021. The company <a href="https://apnews.com/article/stellantis-jeep-ram-ceo-carlos-tavares-6a882961eb47c581e6105d2bc473f57c">told</a> Associated Press on Monday that the look out for a new CEO is part of the normal process of determining leadership succession.
Tavares&#8217; contract is set to expire in 2026, AP reported. There is also a possibility that Tavares will stay in the role for longer, it added.
Earlier this month, President of U.S. Stellantis National Dealer Council (NDC) Kevin Farrish <a href="https://www.benzinga.com/news/24/09/40827607/stellantis-fires-back-at-us-dealer-councils-allegation-of-short-term-decision-making-carmaker-says-p" target="_blank" rel="noreferrer noopener">wrote to company CEO</a> Tavares, accusing him of &#8220;short-term decision-making&#8221; and urged that the CEO spend more to clear older inventory.
Tavares&#8217; decisions, the NDC President said, ended up shrinking the company&#8217;s market share and hurting its many brands. Stellantis, however, said that it takes &#8220;absolute exception&#8221; to the letter, and termed it a &#8220;public personal attack.&#8221;
The company has also faced flack from the United Auto Workers (UAW) union. Last week, <a href="https://www.benzinga.com/news/24/09/40996835/xpeng-touches-production-milestone-of-500k-evs-heres-how-many-electric-cars-the-chinese-company-has">UAW</a> said that it <a href="https://www.benzinga.com/news/24/09/40894503/uaw-files-nlrb-complaint-against-stellantis-over-alleged-contract-violations-says-it-intends-to-make" target="_blank" rel="noreferrer noopener">filed federal unfair labor practice charges</a> at the National Labor Relations Board (NLRB) against Stellantis for alleged violation of the <a href="https://www.benzinga.com/news/23/11/35530931/stellantis-weathered-uaw-strikes-better-than-gm-and-ford-with-less-financial-toll-cfo" target="_blank" rel="noreferrer noopener">labor contract entered into last year</a>.
The union alleges that Stellantis is attempting to move the production of the Dodge Durano SUV out of the U.S. and is also looking to not reopen the idled Belvidere assembly plant in Illinois despite it being promised.
The company, however, said that it has abided with the agreement it entered into last year with the union and will continue to.
Why It Matters: For the first half of 2024, Stellantis reported a 48% fall in net profit to €5.6 billion ($6.22 billion) and a 14% fall in net revenue to €85 billion, owing to a&nbsp;<a href="https://www.benzinga.com/markets/24/06/39477084/stellantis-threatens-to-exit-uk-over-unsustainable-ev-sales-targets-if-this-market-becomes-hostile-f" target="_blank" rel="noreferrer noopener">dip in market share</a>&nbsp;in North America.
"It is an understatement to say that H1 2024 results were disappointing and humbling,"&nbsp;<a href="https://www.benzinga.com/news/earnings/24/07/39959183/stellantis-ceo-earnings-fell-short-of-expectations-expect-20-new-vehicles-this-year" target="_blank" rel="noreferrer noopener">Tavares said</a>&nbsp;at the company's earnings call in July.
&#8220;The Company&#8217;s performance in the first half of 2024 fell short of our expectations, reflecting both a challenging industry context as well as our own operational issues… We have significant work to do, especially in North America, to maximize our long-term potential," he said while also reiterating his personal involvement with the teams in North America to fix the issue.
In the second quarter alone, Stellantis saw its sales in the U.S. fall 21% to 344,993 vehicles.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40996835/xpeng-touches-production-milestone-of-500k-evs-heres-how-many-electric-cars-the-chinese-company-has">XPeng Touches Production Milestone Of 500K EVs: Here&#8217;s How Many Electric Cars The Chinese Company Has Delivered</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

STLA

Stellantis Begins Search For New CEO To Succeed Carlos Tavares: Report

FANG

KNTK

Diamondback Energy, Kinetik And EPIC Midstream Announced A Series Of Transactions To Support The Continued Growth And Strengthened Financial Profile Of EPIC Crude Holdings, LP

Contracts

Teledyne FLIR Defense Receives Two Five-Year Requirements Contracts Worth Up To $47M In Total To Provide And Support Nearly Its Entire Range Of Ground Robots To US Government

Raymond James analyst Josh Beck initiates coverage on Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Market Perform rating.

Initiation

CART

Raymond James Initiates Coverage On Maplebear with Market Perform Rating

SVCO

Silvaco Says It Expanded Its Victory TCAD And Digital Twin Modeling Platform To Planar CMOS, FinFET And Advanced CMOS Technologies

Featured presentations include data from the SYMPHONY Phase 3 trial of AXS-12 in narcolepsy, findings from the CRESCENDO patient survey underscoring the unmet needs of patients with type 1 narcolepsy, and previously reported data on solriamfetol demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with OSA and narcolepsy.

Biotech

Health Care

General

AXSM

Axsome Therapeutics Announced Seven Presentations On AXS-12 And Solriamfetol At Sleep Europe 2024

Wedbush analyst David Chiaverini upgrades Banc of California (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BANC#NYSE">BANC</a>) from Neutral to Outperform and raises the price target from $14 to $18.

Price Target

BANC

Wedbush Upgrades Banc of California to Outperform, Raises Price Target to $18

Ginkgo Bioworks Announced Its New Partnership With NOVUS International To Develop Advanced Feed Additives Designed To Meet The Evolving Needs Of The Animal Agriculture Industry

As part of the partnership, ScottsMiracle-Gro introduced an AI agent built on&nbsp;Google Cloud Vertex AI that functions as the first-of-its-kind&nbsp;&quot;gardening sommelier&quot; and provides highly tailored gardening advice and product recommendations.

GOOG

ScottsMiracle-Gro, Google Cloud Reveal New Collaboration To Help Transform Company's Customer Experience Using Generative AI

EQT And Sixth Street Announced That The EQTInfrastructure IV And EQT Infrastructure V Funds Have Signed An Agreement To Sell A Minority Stake In EdgeConneX To Funds Managed By Sixth Street

Currently available at Dana facilities across Europe, the Dana Certified Reman&trade;&nbsp;program will extend to an additional 50 locations in&nbsp;North America, Europe, the&nbsp;Middle East,&nbsp;Africa, and&nbsp;China&nbsp;by the end of 2025.

Dana Says It Launched Dana Certified Reman Program Boosting Sustainability And Extending Life Cycles Of Drive Technologies For Off-highway

Ahead of the 2024 U.S. presidential election, Donald Trump has made a bold assertion regarding Ukrainian President Volodymyr Zelenskyy and his political preferences.
What Happened: Trump asserted on Tuesday that Zelenskyy prefers the Democrats to win the upcoming 2024 U.S. election, Reuters reported. Trump made this statement during a rally in western Pennsylvania.
Trump&#8217;s remarks contrast with some of his allies who believe Ukraine would welcome his return, claiming he has the skills to negotiate peace with Russian President Vladimir Putin. 
&#8220;I think Zelenskyy is the greatest salesman in history. Every time he comes into the country, he walks away with 60 billion dollars,&#8221; Trump said.
In response, Vice President Kamala Harris&#8217; campaign criticized Trump for not expressing support for Ukraine&#8217;s victory in the war. 
&#8220;Vice President Harris understands that if America walks away from Ukraine, Putin would be sitting in Kyiv with his eyes on the rest of Europe and our NATO allies,&#8221; stated Morgan Finkelstein, Harris&#8217; national security spokesperson.
Zelenskyy&#8217;s office in Kyiv did not immediately comment. Trump provided no specifics on his peace plan, only mentioning he would call Putin and Zelenskyy to negotiate an accord if he wins the election on November 5. Zelenskyy attending the U.N. General Assembly, emphasized that decisive U.S. action could hasten the end of the war.
See Also: <a href="https://www.benzinga.com/news/24/09/40968413/elon-musk-reacts-after-cathie-wood-labels-gavin-newsoms-threat-to-sue-tesla-ceo-over-memes-unconstit?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Cathie Wood Labels Gavin Newsom&#8217;s Threat To Sue Tesla CEO Over Memes &#8216;Unconstitutional&#8217;: &#8216;…But That Didn&#8217;t Stop Them&#8217;</a>
Although Trump mentioned a potential meeting with Zelenskyy no meeting has been scheduled. Over the weekend, Zelenskyy visited a weapons factory in Pennsylvania with Democratic Governor Josh Shapiro, which upset some Trump associates. The visit occurred in a key electoral battleground.
Eastern European Americans, including Ukrainian-Americans and Polish-Americans, have become a crucial voting bloc for both campaigns, especially in Pennsylvania. The U.S. and its allies have provided substantial aid to Ukraine since the Russian invasion began in February 2022.
Why It Matters: The backdrop to Trump&#8217;s claims includes <a href="https://www.benzinga.com/news/24/09/40975071/ukraines-zelenskyy-heads-to-us-to-present-victory-plan-against-russia-to-biden-as-war-drags-for-over">Zelenskyy&#8217;s recent visit </a>to the U.S. to present a &#8220;victory plan&#8221; against Russia to President Joe Biden and other key American leaders.
Additionally, Vice President Kamala Harris has been <a href="https://www.benzinga.com/news/24/09/40811624/kamala-harris-slams-donald-trump-over-friendship-with-russian-president-a-dictator-who-would-eat-you">vocal about her stance</a> on Ukraine, criticizing Trump&#8217;s approach and his &#8220;friendship&#8221; with Putin. Harris emphasized the importance of U.S. support for Ukraine, highlighting the broader implications of the conflict.
Furthermore, Trump has previously claimed to have engaged in <a href="https://www.benzinga.com/news/24/07/39870085/trump-boasts-very-good-phone-call-with-zelenskyy-says-russia-ukraine-will-come-together-and-negotiat">discussions with Zelenskyy</a> about potential peace plans, boasting about a &#8220;very good&#8221; phone call with the Ukrainian leader.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photos courtesy: Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

Global

Trump Says Ukrainian President Backs Kamala Harris For White House: 'Zelenskyy Is The Greatest Salesman In History'

Interactive Strength Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trnr#NASDAQ">TRNR</a>) ("TRNR" or "the Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced that CLMBR has passed EU-wide compliance requirements, has secured the mandatory CE marking and will begin fulfilling orders immediately from exclusive distributors in Germany, Switzerland and Austria.

TRNR

Interactive Strength Successfully Passes EU Compliance for CLMBR and will Start Fulfilling European and UK Orders Immediately

Cyngn Announced The First Build Of The Next-generation 12,000 Lb Drivemod Tugger Has Been Successfully Completed At The Facility Of Its Oem Partner, Motrec International Inc

PayMate India ("PayMate"), a leading provider of B2B payments and services with reputable investors such as Visa &amp; Lightbox, today announced that it has entered into a binding term sheet (the "Proposed Transaction") for the potential acquisition of DigiAsia Bios Pte Ltd., Singapore, a leading Fintech-as-a-Service (FaaS) company in Indonesia and a fully owned subsidiary of DigiAsia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) ("DigiAsia").
Under the terms of the Proposed Transaction, an enterprise valuation of US $400 Million for DigiAsia's business has been determined. Additionally, post the Proposed Transaction, PayMate intends to invest up to US $25 Million in cash, the aggregate financing structure and terms will be finalized in mutual agreement. PayMate and DigiAsia will continue joint due diligence on both entities, identification of the right transaction structure, entering into definitive agreements and the necessary corporate and regulatory approvals of PayMate and DigiAsia which is expected to take up to 60 days. Subsequent to the closing of the Proposed Transaction, PayMate intends to initiate proceedings to list the combined entity in India.

IPOs

FAAS

PayMate to Acquire Fintech-as-a-Service (FaaS) Company DigiAsia Bios for $400M, Plans Indian Market Listing

<div>Mechanistic findings explain ibezapolstat&#39;s properties of lacking cross resistance with other antibiotics and not fostering the emergence of Enterococcus, including vancomycin-resistant strains, a unique differentiation among anti-CDI antibiotics.&nbsp;Planning continues to prepare to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)</div>

Acurx Reports Results From Its Research With Ibezapolstat In Collaboration With Leiden University Medical Center

&nbsp;Initially being applied to unscripted programming, this captioning solution&#39;s innovative technology is transforming the way Warner Bros. Discovery can create and deliver captions, significantly reducing production time and costs, while enhancing the quality of its captioning for domestic viewers.

Warner Bros. Discovery Says It Deployed AI-powered Captioning Solution Built Using Google Cloud AI

<ul>
<li>The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period.</li>
<li>The Company's cash flow break-even target assumes scaling to approximately 40 drug product deliveries per quarter, realizing the 20% reduction in cash operating expenses, and obtaining additional cash resources to extend the Company's cash runway.&nbsp;</li>
</ul>

BLUE

Bluebird Bio Is Implementing A Restructuring Intended To Optimize Its Cost Structure And Enable Quarterly Cash Flow Break-even In 2H Of 2025, Including Reduction In Workforce Of Approximately 25%

VEEV

Veeva Systems Announced The Expansion Of Veeva Vault QMS, Adding New Capabilities To Manage Medtech Field Actions And Product Recalls

Cellectis SA (CLLS) has released an update. Cellectis SA, a clinical-stage biotech company, has just appointed Dr. Adrian Kilcoyne as the new Chief...

Cellectis Boosts Leadership with New CMO

Yanan Zhu, an analyst from Wells Fargo, maintained the Hold rating on Cellectis SA (CLLS – Research Report). The associated price target is $3.00. ...

Cellectis SA: A Balanced Hold Recommendation Amidst Clinical Updates and Strategic Changes

Analyst Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Cellectis SA (CLLS – Research Report) and keeping the price target at $6.00....

Cellectis SA: A Strong Buy on CAR T Advancements and Robust Financial Outlook

Cellectis Non-GAAP EPS of -$0.22 beats by $0.09, revenue of $9.5M misses by $0.2M

Cellectis SA (CLLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 7. Analyst Jack Allen from R...

Cellectis SA: Strong Buy Rating on Robust Pipeline and Financial Stability

Cellectis SA (CLLS) has released an update. Cellectis SA, a clinical-stage biopharmaceutical company, has published research showcasing its breakth...

Cellectis Reveals Promising Cancer Therapy Breakthrough

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Cellectis S.A.: Cheap With Promising But Speculative Cancer Therapies

Cellectis SA (CLLS) has released an update. Cellectis SA, a leader in gene-editing biotechnology, has announced promising pre-clinical results for ...

Cellectis' Breakthrough in TNBC Therapy

Cibus announces proposed public offering of Class A common stock

ALLO

AZNCF

CBUS

CMVLF

IOVA

Press Releases

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

Cellectis Provides Financial Results for the Second Quarter 2024

Management

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Cellectis

Cellectis (CLLS) Forecast

Cellectis (NASDAQ:CLLS) Stock, Quote.Headers.trade-ideas